Total Payments
$5,779
2024 Payments
$974.60
Companies
39
Transactions
338
Medicare Patients
21,887
Medicare Billing
$4.1M
Payment Breakdown by Category
Food & Beverage$5,779 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,779 | 338 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,093 | 60 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $835.64 | 56 | $0 (2024) |
| Allergan, Inc. | $480.26 | 34 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $458.49 | 33 | $0 (2023) |
| Abbott Laboratories | $330.33 | 12 | $0 (2022) |
| PFIZER INC. | $274.93 | 17 | $0 (2024) |
| SCILEX PHARMACEUTICALS INC. | $249.89 | 13 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $205.64 | 10 | $0 (2021) |
| Almatica Pharma LLC | $189.42 | 8 | $0 (2023) |
| Biohaven Pharmaceutical Holding Company Ltd. | $161.71 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $974.60 | 53 | ABBVIE INC. ($413.86) |
| 2023 | $813.52 | 52 | AbbVie Inc. ($279.14) |
| 2022 | $747.83 | 34 | ABBVIE INC. ($216.62) |
| 2021 | $955.28 | 54 | Biohaven Pharmaceuticals, Inc. ($205.64) |
| 2020 | $757.39 | 52 | Allergan, Inc. ($284.76) |
| 2019 | $636.83 | 34 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($144.97) |
| 2018 | $362.05 | 25 | PFIZER INC. ($53.55) |
| 2017 | $531.57 | 34 | Purdue Pharma L.P. ($137.99) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Analgesic | ||||||
| 12/17/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.87 | General |
| Category: Opioid Analgesic | ||||||
| 12/09/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $9.94 | General |
| Category: Opioid Analgesic | ||||||
| 11/13/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: PAIN | ||||||
| 11/06/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.24 | General |
| Category: NEUROLOGY | ||||||
| 11/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: PAIN | ||||||
| 10/31/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $9.13 | General |
| Category: Opioid Analgesic | ||||||
| 10/14/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.64 | General |
| Category: Opioid Analgesic | ||||||
| 09/19/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $23.36 | General |
| 09/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/09/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.45 | General |
| Category: Opioid Analgesic | ||||||
| 08/28/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Neuroscience | ||||||
| 08/26/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.31 | General |
| Category: Opioid Analgesic | ||||||
| 08/13/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.54 | General |
| Category: Opioid Analgesic | ||||||
| 07/24/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Neuroscience | ||||||
| 07/16/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $13.99 | General |
| Category: Opioid Analgesic | ||||||
| 06/25/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $9.33 | General |
| Category: Opioid Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 5,086 | 31,317 | $1.6M | $884,535 |
| 2022 | 32 | 4,787 | 31,463 | $1.7M | $934,877 |
| 2021 | 37 | 5,875 | 25,580 | $2.0M | $1.1M |
| 2020 | 38 | 6,139 | 34,977 | $3.9M | $1.2M |
Total Patients
21,887
Total Services
123,337
Medicare Billing
$4.1M
Procedure Codes
140
All Medicare Procedures & Services
140 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 491 | 2,318 | $347,665 | $230,105 | 66.2% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 306 | 691 | $207,350 | $136,467 | 65.8% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 485 | 2,132 | $127,791 | $71,037 | 55.6% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 306 | 691 | $89,950 | $62,777 | 69.8% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 398 | 1,133 | $135,960 | $49,594 | 36.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 173 | 576 | $67,000 | $48,189 | 71.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 36 | 8,702 | $87,020 | $43,257 | 49.7% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 82 | 115 | $69,000 | $40,324 | 58.4% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 81 | 113 | $36,725 | $22,017 | 60.0% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 360 | 842 | $105,350 | $21,979 | 20.9% |
| 72020 | X-ray of spine, 1 view | Office | 2023 | 359 | 1,007 | $30,210 | $20,175 | 66.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 132 | 132 | $33,000 | $17,416 | 52.8% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 153 | 156 | $23,400 | $16,931 | 72.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 236 | 1,224 | $42,825 | $15,097 | 35.3% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 77 | 90 | $33,550 | $14,387 | 42.9% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Office | 2023 | 33 | 55 | $16,500 | $11,604 | 70.3% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 24 | 50 | $11,250 | $8,656 | 76.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 359 | 837 | $16,700 | $7,806 | 46.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 407 | 8,743 | $43,715 | $7,450 | 17.0% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 76 | 88 | $24,180 | $7,302 | 30.2% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 29 | 38 | $18,650 | $6,157 | 33.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 68 | 111 | $25,000 | $6,096 | 24.4% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 13 | 34 | $10,200 | $4,585 | 45.0% |
| 83986 | Body fluid ph level | Office | 2023 | 235 | 1,213 | $6,059 | $4,256 | 70.2% |
| 64479 | Injection of anesthetic and/or steroid drug into upper or middle spine nerve root using imaging guidance, single level | Office | 2023 | 12 | 13 | $4,725 | $2,799 | 59.2% |
About Dr. Paul Rodriguez, DO
Dr. Paul Rodriguez, DO is a Anesthesiology healthcare provider based in Lighthouse Point, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629057914.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Rodriguez, DO has received a total of $5,779 in payments from pharmaceutical and medical device companies, with $974.60 received in 2024. These payments were reported across 338 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($5,779).
As a Medicare-enrolled provider, Rodriguez has provided services to 21,887 Medicare beneficiaries, totaling 123,337 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 140 distinct procedure/service records.
Ad
Practice Information
- Specialty Anesthesiology
- Other Specialties Pain Medicine
- Location Lighthouse Point, FL
- Active Since 01/13/2006
- Last Updated 03/15/2019
- Taxonomy Code 207L00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629057914
Products in Payments
- XTAMPZA (Drug) $787.85
- UBRELVY (Drug) $646.56
- BOTOX (Biological) $616.06
- NURTEC ODT (Drug) $505.39
- RELISTOR (Drug) $458.49
- QULIPTA (Drug) $267.99
- Movantik (Drug) $195.73
- GRALISE (Drug) $148.44
- iFuse Implant (Device) $132.84
- ZTLido (Drug) $121.24
- PROCLAIM (Device) $120.91
- PENNSAID (Drug) $109.86
- LYRICA (Drug) $106.85
- EMGALITY (Drug) $106.25
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $104.55
- SCS IPGs (Device) $98.64
- SPRIX (Drug) $90.66
- HYSINGLA ER (Drug) $64.48
- BELBUCA (Drug) $62.46
- MOVANTIK (Drug) $61.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.